Together, these results indicate that XLIX can ameliorate the progression of NAFLD and NASH, likely by enhancing the phosphorylation of PPP1CB at Thr316, in a manner that involves WDR6. This evidence concerns the gene PPP1CB and metabolic dysfunction-associated steatohepatitis.